Therapeutic potential of endothelin receptor antagonism in kidney disease

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 310, Issue 5, 2016, Pages R388-R397

  Czopek, Alicja ^a   Moorhouse, Rebecca ^a   Webb, David J ^a   Dhaun, Neeraj ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Endothelin; Kidney; Therapeutics

Indexed keywords

ATRASENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; SPARSENTAN; ZIBOTENTAN; ENDOTHELIN RECEPTOR; LIGAND;

CONTRAST INDUCED NEPHROPATHY; DRUG ANTAGONISM; END STAGE RENAL DISEASE; FLUID RETENTION; HEPATORENAL SYNDROME; HUMAN; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENOVASCULAR DISEASE; REPERFUSION INJURY; REVIEW; SICKLE CELL ANEMIA; ANIMAL; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELINS; HUMANS; KIDNEY; KIDNEY DISEASES; LIGANDS; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION;

EID: 84977767706     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00478.2015     Document Type: Review

References (114)

1. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, du Bois RM, Black CM. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 151: 831-841, 1997.
2. Achmad TH, Rao GS. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 189: 994-1000, 1992.
3. Anand R, Harry D, Holt S, Milner P, Dashwood M, Goodier D, Jarmulowicz M, Moore K. Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. Gut 50: 111-117, 2002.
4. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348: 730-732, 1990.
5. Arfian N, Emoto N, Vignon-Zellweger N, Nakayama K, Yagi K, Hirata K. ET-1 deletion from endothelial cells protects the kidney during the extension phase of ischemia/reperfusion injury. Biochem Biophys Res Commun 425: 443-449, 2012.
6. Arinami T, Ishikawa M, Inoue A, Yanagisawa M, Masaki T, Yoshida MC, Hamaguchi H. Chromosomal assignments of the human endothelin family genes: The endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2-q133. Am J Hum Genet 48: 990-996, 1991.
7. Bachmann-Brandt S, Bittner I, Neuhaus P, Frei U, Schindler R. Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation. Transpl Int 13: 357-362, 2000.
8. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures report of a darusentan-resistant hypertension trial. Hypertension 56: 824-830, 2010.
9. Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P, Jaisser F. Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia. J Am Soc Nephrol. In press.
10. Barton M, Haudenschild CC, D’Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ET(A) receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 95: 14367-14372, 1998.
11. Benigni A, Corna D, Zoja C, Longaretti L, Gagliardini E, Perico N, Coffman TM, Remuzzi G. Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. J Am Soc Nephrol 15: 2666-2674, 2004.
12. Best PJM, McKenna CJ, Hasdai D, Holmes DRJ, Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolaemia. Circulation 99: 1747-1752, 1999.
13. Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, Gerber MJ. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 9: 760-769, 2007.
14. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjorklund-Bodegard K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O’Brien E, Staessen JA. International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 370: 1219-1229, 2007.
15. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 14: 2199-2210, 2003.
16. Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 82: 388-400, 2012.
17. Brooks DP, DePalma PD. Blockade of radiocontrast-induced nephrotoxicity by the endothelin receptor antagonist, SB 209670. Nephron 72: 629-636, 1996.
18. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10: 213-218, 1978.
19. Chade AR, Stewart NJ, Peavy PR. Disparate effects of single endothelin-A and-B receptor blocker therapy on the progression of renal injury in advanced renovascular disease. Kidney Int 85: 833-844, 2014.
20. Chang MY, Parker E, El Nahas M, Haylor JL, Ong AC. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18: 560-569, 2007.
21. Clavell AL, Burnett JCJ. Physiologic and pathophysiologic roles of endothelin in the kidney. Curr Opin Nephrol Hypertens 3: 66-72, 1994.
22. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Pharmacology and genetic modifications of the endothelin system. Pharmacol Rev. doi: 10.1124/pr.115.011833.
23. Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med 166: 846-852, 2006.
24. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302: 1782-1789, 2009.
25. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25: 1083-1093, 2014.
26. Denton CP. Renal manifestations of systemic sclerosis-clinical features and outcome assessment. Rheumatology (Oxford) 47, Suppl 5: v54-v56, 2008.
27. Denton KM, Shweta A, Finkelstein L, Flower RL, Evans RG. Effect of endothelin-1 on regional kidney blood flow and renal arteriole calibre in rabbits. Clin Exp Pharmacol Physiol 31: 494-501, 2004.
28. Dhaun N, Ferro CJ, Davenport AP, Haynes WG, Goddard J, Webb DJ. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 22: 3228-3234, 2007.
29. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 17: 943-955, 2006.
30. Dhaun N, Lilitkarntakul P, Macintyre IM, Muilwijk E, Johnston NR, Kluth DC, Webb DJ, Goddard J. Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. Am J Physiol Renal Physiol 296: F1477-F1483, 2009.
31. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J, Webb DJ. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57: 772-779, 2011.
32. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 54: 113-119, 2009.
33. Dhaun N, Melville V, Blackwell S, Talwar DK, Johnston NR, Goddard J, Webb DJ. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol 24: 31-36, 2013.
34. Dhaun N, Moorhouse R, MacIntyre IM, Melville V, Oosthuyzen W, Kimmitt RA, Brown KE, Kennedy ED, Goddard J, Webb DJ. Diurnal variation in blood pressure and arterial stiffness in chronic kidney disease: the role of endothelin-1. Hypertension 64: 296-304, 2014.
35. Dhaun N, Pollock DM, Goddard J, Webb DJ. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 28: 573-579, 2007.
36. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Kottgen A, Levey AS, Levin A. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382: 158-169, 2013.
37. Ergun S, Harneit S, Paust HJ, Mukhopadhyay AK, Holstein AF. Endothelin and endothelin receptors A and B in the human testis. Anat Embryol (Berl) 199: 207-214, 1999.
38. Feng Y, Zhang Q, Dai DZ, Ying HJ, Dai Y. Strontium fructose 1,6-diphosphate rescues adenine-induced male hypogonadism and upregulates the testicular endothelin-1 system. Clin Exp Pharmacol Physiol 34: 1131-1137, 2007.
39. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97: 2323-2330, 1998.
40. Forbes JM, Hewitson TD, Becker GJ, Jones CL. Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int 59: 1333-1341, 2001.
41. Fujisaki K, Kubo M, Masuda K, Tokumoto M, Hirakawa M, Ikeda H, Matsui R, Matsuo D, Fukuda K, Kanai H, Hirakata H, Iida M. Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function. Clin Exp Nephrol 7: 279-283, 2003.
42. Fuquay R, Renner B, Kulik L, McCullough JW, Amura C, Strassheim D, Pelanda R, Torres R, Thurman JM. Renal ischemiareperfusion injury amplifies the humoral immune response. J Am Soc Nephrol 24: 1063-1072, 2013.
43. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382: 339-352, 2013.
44. Giusti R, Neri M, Angelini D, Carlini A, Fiorini I, Bigongiari P, Antonelli A. Plasma concentration of endothelin and arterial pressure in patients with ADPKD. Contrib Nephrol 115: 118-121, 1995.
45. Goddard J, Johnston NR, Cumming AD, Webb DJ. Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. Am J Physiol Renal Physiol 293: F1433-F1438, 2007.
46. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 109: 1186-1193, 2004.
47. Hatzipantelis ES, Pana ZD, Gombakis N, Taparkou A, Tzimouli V, Kleta D, Zafeiriou DJ, Garipidou V, Kanakoudi F, Athanassiou M. Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease. Int J Hematol 98: 158-163, 2013.
48. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344: 852-854, 1994.
49. Heimlich JB, Speed JS, O’Connor PM, Pollock JS, Townes TM, Meiler SE, Kutlar A, Pollock DM. Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species. Br J Pharmacol 2015 Nov 12. doi:10.1111/bph.13380.
50. Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M, Epstein FH. Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 3: 58-65, 1992.
51. Hocher B, Kalk P, Slowinski T, Godes M, Mach A, Herzfeld S, Wiesner D, Arck PC, Neumayer HH, Nafz B. ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease. J Am Soc Nephrol 14: 367-376, 2003.
52. Hocher B, Liefeldt L, Thone-Reineke C, Orzechowski HD, Distler A, Bauer C, Paul M. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 28: 196-201, 1996.
53. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Schleuning WD, Theuring F. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99: 1380-1389, 1997.
54. Hsu CY. Where is the epidemic in kidney disease? J Am Soc Nephrol 21: 1607-1611, 2010.
55. Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 104: 864-869, 2001.
56. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86: 2863-2867, 1989.
57. Investigators A, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361: 1953-1962, 2009.
58. Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P, Provost D, Hoffmann K, Fischer Y, Hocher B. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension 57: 755-763, 2011.
59. Karet FE, Davenport AP. Localization of endothelin peptides in human kidney. Kidney Int 49: 382-387, 1996.
60. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 29: 2-26, 1997.
61. Kohan DE. Role of collecting duct endothelin in control of renal function and blood pressure. Am J Physiol Regul Integr Comp Physiol 305: R659-R668, 2013.
62. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22: 763-772, 2011.
63. Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, Valentine M, Barton D, Durham SK. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 146: 819-826, 1995.
64. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 96: 11496-11500, 1999.
65. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R. Acute kidney injury: an increasing global concern. Lancet 382: 170-179, 2013.
66. Lankhorst S, Danser AH, van den Meiracker. Endothelin-1 AH, antiangiogenesis. Am J Physiol Regul Integr Comp Physiol 310: R230-R234, 2016.
67. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325: 997-1001, 1991.
68. Levey AS, Coresh J. Chronic kidney disease. Lancet 379: 165-180, 2012.
69. Liss PCP, Nygren A, Palm F, Hansell P. Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia. Acta Radiol 44: 111-117, 2003.
70. Mallick NP, Short CD, Hunt LP. How far since Ellis? The Manchester Study of glomerular disease. Nephron 46: 113-124, 1987.
71. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G, Group AS. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21: 527-535, 2010.
72. Margulies KB, Hildebrand FL, Heublein DM, Burnett JCJ. Radiocontrast increases plasma and urinary endothelin. J Am Soc Nephrol 2: 1041-1045, 1991.
73. McEniery CM, Qasem A, Schmitt M, Avolio AP, Cockcroft JR, Wilkinson IB. Endothelin-1 regulates arterial pulse wave velocity in vivo. J Am Coll Cardiol 42: 1975-1981, 2003.
74. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327: 1774-1778, 1992.
75. Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C, Galbusera M, Gastoldi S, Mundel P, Remuzzi G, Benigni A. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 166: 1309-1320, 2005.
76. Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92: 2148-2152, 2005.
77. Munemura C, Uemasu J, Kawasaki H. Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: possible evidence of heterogeneity in cystogenesis. Am J Kidney Dis 24: 561-568, 1994.
78. Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol 11: 161-171, 2015.
79. Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD. Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 13: 170-176, 1998.
80. Ong AC, Jowett TP, Firth JD, Burton S, Kitamura M, Fine LG. Human tubular-derived endothelin in the paracrine regulation of renal interstitial fibroblast function. Exp Nephrol 2: 134, 1994.
81. Ong AC, von Websky K, Hocher B. Endothelin and tubulointerstitial renal disease. Semin Nephrol 35: 197-207, 2015.
82. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 43: 354-358, 1993.
83. Parvanova A, van der Meer IM, Iliev I, Perna A, Gaspari F, Trevisan R, Bossi A, Remuzzi G, Benigni A, Ruggenenti P. Daglutril in Diabetic Nephropathy Study G. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 1: 19-27, 2013.
84. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100: 485-494, 2007.
85. Pernow J, Franco-Cereceda A, Matran R, Lundberg JM. Effect of endothelin-1 on regional vascular resistance in the pig. J Cardiovasc Pharmacol 13, Suppl 16: S205-S206, 1989.
86. Plato CF, Garvin JL. Nitric oxide, endothelin and nephron transport: potential interactions. Clin Exp Pharmacol Physiol 26: 262-268, 1999.
87. Pollock DM, Polakowski JS, Wegner CD, Opgenorth TJ. Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy. Ren Fail 19: 753-761, 1997.
88. Raina A, Horn ET, Benza RL. The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists. Transplantation 94: 885-893, 2012.
89. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
90. Riggleman A, Harvey J, Baylis C. Endothelin mediates some of the renal actions of acutely administered angiotensin II. Hypertension 38: 105-109, 2001.
91. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63: 2254-2261, 2003.
92. Sabaa N, de Franceschi L, Bonnin P, Castier Y, Malpeli G, Debbabi H, Galaup A, Maier-Redelsperger M, Vandermeersch S, Scarpa A, Janin A, Levy B, Girot R, Beuzard Y, Leboeuf C, Henri A, Germain S, Dussaule JC, Tharaux PL. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 118: 1924-1933, 2008.
93. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 348: 732-735, 1990.
94. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14: 83S-89S, 2001.
95. Sharkovska Y, Kalk P, von Websky K, Relle K, Pfab T, Alter M, Fischer Y, Hocher B. Renoprotective effects of combined endothelinconverting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab 57: 507-515, 2011.
96. Smolander J, Vogt B, Maillard M, Zweiacker C, Littke T, Hengelage T, Burnier M. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin Pharmacol Ther 85: 628-634, 2009.
97. Tharaux PL, Hagege I, Placier S, Vayssairat M, Kanfer A, Girot R, Dussaule JC. Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant 20: 2408-2413, 2005.
98. Thomas B, Wulf S, Bikbov B, Perico N, Cortinovis M, Courville de Vaccaro K, Flaxman A, Peterson H, Delossantos A, Haring D, Mehrotra R, Himmelfarb J, Remuzzi G, Murray C, Naghavi M. Maintenance dialysis throughout the world in years 1990 and 2010. J Am Soc Nephrol 26: 2621-2633, 2015.
99. Thone-Reinke C, Simon K, Richter CM, Godes M, Neumayer HH, Thormahlen D, Hocher B. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol 44, Suppl 1: S76-S79, 2004.
100. Totsune K, Mouri T, Takahashi K, Ohneda M, Sone M, Saito T, Yoshinaga K. Detection of immunoreactive endothelin in plasma of hemodialysis patients. FEBS Lett 249: 239-242, 1989.
101. Tullos NA, Stewart NJ, Davidovich R, Chade AR. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease. Nephrol Dial Transplant 30: 584-593, 2015.
102. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C. Beginning, ending supportive therapy for the kidney. I. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294: 813-818, 2005.
103. van Walraven C, Manuel DG, Knoll G. Survival trends in ESRD patients compared with the general population in the United States. Am J Kidney Dis 63: 491-499, 2014.
104. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG. University of Toronto Acute Kidney Injury Research G. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302: 1179-1185, 2009.
105. Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, Szerlip H, Thames MD, Davidson CJ, Shusterman N, Schwab SJ. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 57: 1675-1680, 2000.
106. Webb DJ. DORADO: Opportunity postponed lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension 56: 806-807, 2010.
107. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374: 1423-1431, 2009.
108. Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, Philipp T, Mitchell A. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20: 655-664, 2009.
109. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation 105: 213-217, 2002.
110. Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 47: 160-168, 2008.
111. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
112. Zager RA, Johnson AC, Andress D, Becker K. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int 84: 703-712, 2013.
113. Zhang C, Yeh S, Chen YT, Wu CC, Chuang KH, Lin HY, Wang RS, Chang YJ, Mendis-Handagama C, Hu L, Lardy H, Chang C. Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proc Natl Acad Sci USA 103: 17718-17723, 2006.
114. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, Ronco P, Remuzzi G. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 26: 934-941, 1995.